ALKS 株価分析 — ALKERMES PLC (Healthcare >> Drug Manufacturers - Specialty & Generic)
ALKS に関するよくある質問
ALKSのPER(株価収益率)は?
ALKERMES PLC(ALKS)は現在PER 63.30倍で取引されています。
ALKSのROE(自己資本利益率)は?
ALKERMES PLCのROEは3.66%です。
ALKSの配当利回りは?
ALKERMES PLCの配当利回りは0.00%です。
ALKSの品質スコア(Quality Score)は?
当社のAIはALKSの総合財務品質を100点中15点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ALKSは今が買い時ですか?
当社AIのタイミングスコアは100点中66点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ALKSはどのセクターに属しますか?
ALKERMES PLCはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます(NASDAQ市場)
ALKS AI Analysis Summary
Our AI summary for ALKS: ALKERMES PLC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 63.30, ROE of 3.66%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 66/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 48.99
Price
-1.04
(-2.08%)
Day Change
|
|
|---|
ALKS, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
1868
|
| Magic Formula Rank by ROE |
1868
|
| Magic Formula Rank by ROIC |
1538
|
| Price | 48.99 |
| PBV / Sector |
4.64 / 3.22
|
| Earning Per Share | 0.39 |
| PE / Sector |
63.30 / 29.79
|
| PEG or PE/Growth / Sector |
-0.55 / 0.13
|
| Average 1M Daily Value |
91.66 M
|
| Average 1W Daily Value |
119.80 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
58% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:27 |
| Symbol | ALKS |
| Name | ALKERMES PLC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 167.76 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8,393.20 / 10,754.62 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Connaught House, Dublin, Ireland, D04 C5Y6
Phone: 353 1 772 8000
Website: https://www.alkermes.com
Employees: 2,050
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google